US 12,257,225 B2
Polyoxometalate complexes and pharmaceutical compositions
Jie Song, Atlanta, GA (US); Shuming Nie, Atlanta, GA (US); and Craig Hill, Atlanta, GA (US)
Assigned to Emory University, Atlanta, GA (US)
Filed by Emory University, Atlanta, GA (US)
Filed on May 13, 2022, as Appl. No. 17/744,369.
Application 17/744,369 is a division of application No. 16/345,578, granted, now 11,331,297, previously published as PCT/US2017/058563, filed on Oct. 26, 2017.
Claims priority of provisional application 62/469,340, filed on Mar. 9, 2017.
Claims priority of provisional application 62/413,404, filed on Oct. 26, 2016.
Prior Publication US 2022/0273606 A1, Sep. 1, 2022
Int. Cl. A61K 31/28 (2006.01); A61K 31/282 (2006.01); A61K 33/243 (2019.01); A61P 35/00 (2006.01); B32B 21/02 (2006.01); C07C 229/00 (2006.01); C09D 5/02 (2006.01); C09D 5/08 (2006.01); C09D 7/65 (2018.01)
CPC A61K 31/28 (2013.01) [A61K 31/282 (2013.01); A61K 33/243 (2019.01); A61P 35/00 (2018.01); B32B 21/02 (2013.01); C07C 229/00 (2013.01); C09D 5/02 (2013.01); C09D 5/08 (2013.01); C09D 7/65 (2018.01)] 14 Claims
OG exemplary drawing
 
1. A pharmaceutical composition in the form of a pill, capsule, tablet, bead, granule, or micronized particle comprising [V6O13{(OCH2)3CNH3}2] zwitterionic salt and a pharmaceutically acceptable excipient.